We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes. (TriMaster)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02653209
Recruitment Status : Completed
First Posted : January 12, 2016
Last Update Posted : April 1, 2021
University of Exeter
NHS Tayside
University of Dundee
University of Glasgow
Newcastle University
King's College London
Information provided by (Responsible Party):
Royal Devon and Exeter NHS Foundation Trust

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : January 2021
Actual Study Completion Date : January 2021
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 December 8, 2022